Top

Hormones

Published in:

01-09-2020 | Glucocorticoid | Original Article

Serum cortisone and glucocorticoid receptor gene (NR3C1) polymorphism in human dysglycemia

Authors: Dandan Wei, Xue Liu, Wenqian Huo, Songcheng Yu, Linlin Li, Chongjian Wang, Zhenxing Mao

Published in: Hormones | Issue 3/2020

Abstract

Purpose

We aimed to explore the associations of serum cortisone and glucocorticoid receptor (GR) polymorphism with glucose metabolism and type 2 diabetes mellitus (T2DM) among Chinese adults.

Methods

A total of 2315 participants were included in the present study. Serum cortisone was measured by liquid chromatography-tandem mass spectrometry. Multivariable logistic regression and linear regression were employed to assess the associations between serum cortisone and different glucose metabolism status.

Results

Serum cortisone was positively associated with impaired fasting glucose (IFG) and T2DM ((Quartile 4 vs Quartile 1, odds ratio (OR) = 1.36, 95% confidence interval (CI) 1.01, 1.84, and OR = 2.08, 95% CI 1.50, 2.89, respectively)). A 100% increase in cortisone was associated with a 0.015 (95% CI 0.005, 0.025) mg/dl higher fasting plasma glucose (FPG), a 0.007 (95% CI 0.001, 0.013) higher glycosylated hemoglobin (HbA1c), a 0.4% (95% CI − 0.007, 0.000) lower HOMA2-IR, and a 58.1% (95% CI − 0.788, − 0.373) lower HOMA2-β. After stratification by genotype, the association between serum cortisone and T2DM was not significant in TT genotype carriers. In addition, at the higher concentrations of cortisone, TT genotype carriers had a lower FPG, HbA1c, and HOMA2-IR and a higher HOMA2-β than GG and GT carriers.

Conclusions

Elevated serum cortisone was associated with an increased risk of IFG and T2DM, and the associations may be modified by rs9324924 polymorphism.

Available only for authorised users

Loerz C, Maser E (2017) The cortisol-activating enzyme 11beta-hydroxysteroid dehydrogenase type 1 in skeletal muscle in the pathogenesis of the metabolic syndrome. J Steroid Biochem Mol Biol 174:65–71. https://doi.org/10.1016/j.jsbmb.2017.07.030

Koper JW, van Rossum EFC, van den Akker ELT (2014) Glucocorticoid receptor polymorphisms and haplotypes and their expression in health and disease. Steroids 92:62–73CrossRef

Qi L, Hu FB, Hu G (2008) Genes, environment, and interactions in prevention of type 2 diabetes: a focus on physical activity and lifestyle changes. Curr Mol Med 8(6):519–532CrossRef

Cho NH, Shaw JE, Karuranga S, et al (2017) IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pr 2018; 138:271–281. doi: https://doi.org/10.1016/j.diabres.2018.02.023

Oster H, Challet E, Ott V et al The functional and clinical significance of the 24-hour rhythm of circulating glucocorticoids. Endocrine reviews 38(1):3–45. https://doi.org/10.1210/er.2015-1080

Rafacho A, Ortsater H, Nadal A, Quesada I (2014) Glucocorticoid treatment and endocrine pancreas function: implications for glucose homeostasis, insulin resistance and diabetes. J Endocrinol 223(3):R49–R62. https://doi.org/10.1530/JOE-14-0373CrossRefPubMed

Gulliford MC, Charlton J, Latinovic R (2006) Risk of diabetes associated with prescribed glucocorticoids in a large population. Diabetes Care 29(12):2728–2729CrossRef

Kamba A, Daimon M, Murakami H et al (2016) Association between higher serum cortisol levels and decreased insulin secretion in a general population. PLoS One 11(11):e0166077. https://doi.org/10.1371/journal.pone.0166077CrossRefPubMedPubMedCentral

Adam TC, Hasson RE, Ventura EE et al (2010) Cortisol is negatively associated with insulin sensitivity in overweight Latino youth. J Clin Endocr Metab 95(10):4729–4735. https://doi.org/10.1210/jc.2010-0322CrossRefPubMed

10.

Ortiz R, Kluwe B, Odei JB et al (2018) The association of morning serum cortisol with glucose metabolism and diabetes: the Jackson heart study. Psychoneuroendocrinology. 103:25–32. https://doi.org/10.1016/j.psyneuen.2018.12.237CrossRefPubMedPubMedCentral

11.

Homma M, Tanaka A, Hino K et al (2001) Assessing systemic 11beta-hydroxysteroid dehydrogenase with serum cortisone/cortisol ratios in healthy subjects and patients with diabetes mellitus and chronic renal failure. Metab Clin Exp 50(7):801–804CrossRef

12.

Anderson JL, Carlquist JF, Roberts WL et al (2007) Asymmetric dimethylarginine, cortisol/cortisone ratio, and C-peptide: markers for diabetes and cardiovascular risk? Am Heart J 153(1):67–73CrossRef

13.

Spanakis EK, Wang X, Sanchez BN et al (2016) Lack of significant association between type 2 diabetes mellitus with longitudinal change in diurnal salivary cortisol: the multiethnic study of atherosclerosis. Endocrine 53(1):227–239. https://doi.org/10.1007/s12020-016-0887-8CrossRefPubMedPubMedCentral

14.

Giordano R, Marzotti S, Berardelli R et al (2012) BClI polymorphism of the glucocorticoid receptor gene is associated with increased obesity, impaired glucose metabolism and dyslipidaemia in patients with Addison’s disease. Clin Endocrinol 77(6):863–870. https://doi.org/10.1111/j.1365-2265.2012.04439.xCrossRef

15.

Roussel R, Reis AF, Dubois-Laforgue D, Bellanne-Chantelot C, Timsit J, Velho G (2003) The N363S polymorphism in the glucocorticoid receptor gene is associated with overweight in subjects with type 2 diabetes mellitus. Clin Endocrinol 59(2):237–241CrossRef

16.

Rosmond R, Holm G (2008) A 5-year follow-up study of 3 polymorphisms in the human glucocorticoid receptor gene in relation to obesity, hypertension, and diabetes. Journal of the cardiometabolic syndrome 3(3):132–135. https://doi.org/10.1111/j.1559-4572.2008.00008.xCrossRefPubMed

17.

Liu X, Wu W, Mao Z et al (2018) Prevalence and influencing factors of overweight and obesity in a Chinese rural population: the Henan rural cohort study. Sci Rep 8(1):13101. https://doi.org/10.1038/s41598-018-31336-2CrossRefPubMedPubMedCentral

18.

Zhang HQ, Li YQ, Mao ZX et al (2008) A dose-response association of night sleep duration with hypertension in a Chinese rural population: the Henan rural cohort study. Journal Of the American Society Of Hypertension 12(12):867–879. https://doi.org/10.1016/j.jash.2018.10.005CrossRef

19.

Wallace TM, Levy JC, Matthews DR (2004) Use and abuse of HOMA modeling. Diabetes Care 27(6):1487–1495CrossRef

20.

Debono M, Harrison RF, Whitaker MJ et al (2016) Salivary cortisone reflects cortisol exposure under physiological conditions and after hydrocortisone. J Clin Endocrinol Metab 101(4):1469–1477. https://doi.org/10.1210/jc.2015-3694CrossRefPubMed

21.

Lehrer HM, Dubois SK, Maslowsky J et al (2016) Hair cortisol concentration and glycated hemoglobin in African American adults. Psychoneuroendocrinology 72:212–218. https://doi.org/10.1016/j.psyneuen.2016.06.018CrossRefPubMed

22.

Darmon P, Dadoun F, Boullu-Ciocca S et al (2006) Insulin resistance induced by hydrocortisone is increased in patients with abdominal obesity. Am J Phys Endocrinol Metab 291(5):E995–e1002CrossRef

23.

Zhou PZ, Zhu YM, Zou GH et al (2016) Relationship between glucocorticoids and insulin resistance in healthy individuals. Medical science monitor: international medical journal of experimental and clinical research 22:1887–1894CrossRef

24.

Johar H, Emeny RT, Bidlingmaier M et al (2016) Sex-related differences in the association of salivary cortisol levels and type 2 diabetes. Findings from the cross-sectional population based KORA-age study. Psychoneuroendocrinology 69:133–141. https://doi.org/10.1016/j.psyneuen.2016.04.004

25.

Majer-Lobodzinska A, Adamiec-Mroczek J (2017) Glucocorticoid receptor polymorphism in obesity and glucose homeostasis. Advances in clinical and experimental medicine: official organ Wroclaw Medical University 26(1):143–148. https://doi.org/10.17219/acem/41231CrossRef

26.

Lin RC, Wang XL, Dalziel B et al (2003) Association of obesity, but not diabetes or hypertension, with glucocorticoid receptor N363S variant. Obes Res 11(6):802–808CrossRef

27.

Dobson MG, Redfern CP, Unwin N et al (2001) The N363S polymorphism of the glucocorticoid receptor: potential contribution to central obesity in men and lack of association with other risk factors for coronary heart disease and diabetes mellitus. J Clin Endocrinol Metab 86(5):2270–2274PubMed

28.

Di Dalmazi G, Pagotto U, Pasquali R et al (2012) Glucocorticoids and type 2 diabetes: from physiology to pathology. Journal of nutrition and metabolism 2012:525093. https://doi.org/10.1155/2012/525093CrossRefPubMedPubMedCentral

29.

Pilkis SJ, El-Maghrabi MR, Claus TH (1988) Hormonal regulation of hepatic gluconeogenesis and glycolysis. Annu Rev Biochem 57:755–783CrossRef

30.

Kuo T, McQueen A, Chen TC et al (2015) Regulation of glucose homeostasis by glucocorticoids. Adv Exp Med Biol 872:99–126. https://doi.org/10.1007/978-1-4939-2895-8_5CrossRefPubMedPubMedCentral

31.

Beaudry JL, Riddell MC (2012) Effects of glucocorticoids and exercise on pancreatic beta-cell function and diabetes development. Diabetes Metab Res Rev 28(7):560–573. https://doi.org/10.1002/dmrr.2310CrossRefPubMed

32.

van Rossum EF, Lamberts SW (2004) Polymorphisms in the glucocorticoid receptor gene and their associations with metabolic parameters and body composition. Recent Prog Horm Res 59:333–357CrossRef

33.

Cherkas A, Eckl P, Gueraud F et al (2016) Helicobacter pylori in sedentary men is linked to higher heart rate, sympathetic activity, and insulin resistance but not inflammation or oxidative stress. Croat Med J 57(2):141–149CrossRef

34.

Cherkas A, Golota S, Guéraud F et al (2018) A helicobacter pylori-associated insulin resistance in asymptomatic sedentary young men does not correlate with inflammatory markers and urine levels of 8-iso-PGF2-α or 1,4-dihydroxynonane mercapturic acid. Arch Physiol Biochem 124(3):275–285. https://doi.org/10.1080/13813455.2017.1396346CrossRefPubMed

35.

Cherkas A, Abrahamovych O, Golota S et al (2015) The correlations of glycated hemoglobin and carbohydrate metabolism parameters with heart rate variability in apparently healthy sedentary young male subjects. Redox Biol 5:301–307. https://doi.org/10.1016/j.redox.2015.05.007CrossRefPubMedPubMedCentral

Title: Serum cortisone and glucocorticoid receptor gene (NR3C1) polymorphism in human dysglycemia
Authors: Dandan Wei
Xue Liu
Wenqian Huo
Songcheng Yu
Linlin Li
Chongjian Wang
Zhenxing Mao
Publication date: 01-09-2020
Publisher: Springer International Publishing
Keywords: Glucocorticoid
Type 2 Diabetes
Published in: Hormones / Issue 3/2020
Print ISSN: 1109-3099
Electronic ISSN: 2520-8721
DOI: https://doi.org/10.1007/s42000-020-00196-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2020

Metabolic and catecholamine response to sympathetic stimulation in early-treated adult male patients with phenylketonuria

Relationship of thyroid dysfunction with cardiovascular diseases: updated review on heart failure progression

The role of carbohydrate counting in glycemic control and oxidative stress in patients with type 1 diabetes mellitus (T1DM)

A closer look at NIFTP

Minding the gap between cortisol levels measured with second-generation assays and current diagnostic thresholds for the diagnosis of adrenal insufficiency: a single-center experience

Hyperthyroxinemia with a non-suppressed TSH: how to confidently reach a diagnosis in this clinical conundrum

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials